Eligibility criteria for Menopausal Hormone Therapy (MHT): a position statement from a consortium of scientific societies for the use of MHT in women with medical conditions. MHT Eligibility Criteria Group

被引：25

作者：

Mendoza, Nicolas ^{[1
]}

Ramirez, Isabel ^{[1
]}

de la Viuda, Esther ^{[1
]}

Coronado, Pluvio ^{[1
]}

Baquedano, Laura ^{[1
]}

Llaneza, Placido ^{[1
]}

Nieto, Veronica ^{[1
]}

Otero, Borja ^{[1
]}

Sanchez-Mendez, Sonia ^{[1
]}

Alvarez de Frutos, Visitacion ^{[2
]}

Andraca, Leire ^{[3
]}

Barriga, Patricio ^{[4
]}

Benitez, Zully ^{[5
]}

Bombas, Teresa ^{[4
]}

Jesus Cancelo, Ma ^{[6
]}

Cano, Antonio ^{[7
]}

Castelo Branco, Camil ^{[8
]}

Correa, Marta ^{[9
]}

Luis Doval, Jose ^{[1
]}

Fasero, Maria ^{[1
]}

Fiol, Gabriel ^{[1
]}

Garello, Nestor C. ^{[10
]}

Genazzani, Andrea R. ^{[8
]}

Isabel Gomez, Ana ^{[11
]}

Angeles Gomez, Ma ^{[1
]}

Gonzalez, Silvia ^{[1
]}

Goulis, Dimitrios G. ^{[7
]}

Guinot, Misericordia ^{[1
]}

Rolando Hernandez, Luis ^{[10
]}

Herrero, Sonia ^{[12
]}

Iglesias, Eva ^{[1
]}

Rosa Jurado, Ana ^{[13
]}

Lete, Inaki ^{[1
]}

Lubian, Daniel ^{[1
]}

Martinez, Milagros ^{[1
]}

Nieto, Anibal ^{[1
]}

Nieto, Laura ^{[1
]}

Palacios, Santiago ^{[14
]}

Pedreira, Milagros ^{[15
]}

Perez-Campos, Ezequiel ^{[1
]}

Pla, Maria Jesus ^{[16
]}

Presa, Jesus ^{[1
]}

Quereda, Francisco ^{[1
]}

Ribes, Miriam ^{[1
]}

Romero, Pablo ^{[1
]}

Roca, Beatriz ^{[1
]}

Sanchez-Capilla, Antonio ^{[17
]}

Sanchez-Borrego, Rafael ^{[18
]}

Santaballa, Ana ^{[19
]}

Santamaria, Amparo ^{[20
]}

机构：

[1] Assoc Espanola Estudio Menopausia AEEM, Madrid, Spain

[2] Soc Espanola Endocrinol & Nutr SEEN, Madrid, Spain

[3] Soc Espanola Farm Comunitaria SEFAC, Madrid, Spain

[4] Red Iberoamer Salud Sexual & Reprod REDISSER, Madrid, Spain

[5] Federac Latino Amer Soc Climaterio & Menopausia F, Madrid, Spain

[6] Soc Espanola Ginecol & Obstet SEGO, Madrid, Spain

[7] European Menopause & Andropause Soc EMAS, Madrid, Spain

[8] European Soc Gynecol ESG, Madrid, Spain

[9] Soc Espanola Contracepc SEC, Madrid, Spain

[10] Federac Latino Amer Soc Obstet & Ginecol FLASOG, Madrid, Spain

[11] Soc Espanola Senol & Patol Mamaria SESPM, Madrid, Spain

[12] Soc Espanola Trombosis & Hemostasia SETH, Madrid, Spain

[13] Soc Espanola Med Atenc Primaria SEMERGEN, Madrid, Spain

[14] Int Menopause Soc IMS, Madrid, Spain

[15] Soc Espanola Cardiol SEC, Madrid, Spain

[16] Secc Ginecol Oncol SEGO, Madrid, Spain

[17] Soc Espanola Patol Digest SEPD, Madrid, Spain

[18] Fdn Espanola Estudio Menopausia FEEM, Madrid, Spain

[19] Soc Espanola Oncol Med SEOM, Madrid, Spain

[20] Soc Espanola Hernatol & Hemoterapia SEHH, Madrid, Spain

[21] Int Soc Gynecol Endocrinol ISGE, Madrid, Spain

[22] Soc Espanola Obesidad SEED, Madrid, Spain

来源：

MATURITAS | 2022年 / 166卷

关键词：

Menopausal hormone therapy; Menopause; Eligibility criteria; Medical conditions; ESTROGEN-REPLACEMENT THERAPY; ORAL-CONTRACEPTIVE STEROIDS; ACUTE MYOCARDIAL-INFARCTION; HEALTHY POSTMENOPAUSAL WOMEN; AMBULATORY BLOOD-PRESSURE; CONTINUOUS COMBINED HRT; CARDIOVASCULAR RISK-FACTORS; CONJUGATED EQUINE ESTROGEN; PLACEBO-CONTROLLED TRIAL; BREAST-CANCER SURVIVORS;

D O I：

10.1016/j.maturitas.2022.08.008

中图分类号：

R592 [老年病学]; C [社会科学总论];

学科分类号：

03 ; 0303 ; 100203 ;

摘要：

This project aims to develop eligibility criteria for menopausal hormone therapy (MHT). The tool should be similar to those already established for contraception A consortium of scientific societies coordinated by the Spanish Menopause Society met to formulate recommendations for the use of MHT by women with medical conditions based on the best available evidence. The project was developed in two phases. As a first step, we conducted 14 systematic reviews and 32 metanalyses on the safety of MHT (in nine areas: age, time of menopause onset, treatment duration, women with thrombotic risk, women with a personal history of cardiovascular disease, women with metabolic syndrome, women with gastrointestinal diseases, survivors of breast cancer or of other cancers, and women who smoke) and on the most relevant pharmacological interactions with MHT. These systematic reviews and metanalyses helped inform a structured process in which a panel of experts defined the eligibility criteria according to a specific framework, which facilitated the discussion and development process. To unify the proposal, the following eligibility criteria have been defined in accordance with the WHO international nomenclature for the different alternatives for MHT (category 1, no restriction on the use of MHT; category 2, the benefits outweigh the risks; category 3, the risks generally outweigh the benefits; category 4, MHT should not be used). Quality was classified as high, moderate, low or very low, based on several factors (including risk of bias, inaccuracy, inconsistency, lack of directionality and publication bias). When no direct evidence was identified, but plausibility, clinical experience or indirect evidence were available, "Expert opinion" was categorized. For the first time, a set of eligibility criteria, based on clinical evidence and developed according to the most rigorous methodological tools, has been defined. This will provide health professionals with a powerful decision-making tool that can be used to manage menopausal symptoms.

引用

页码：65 / 85

页数：21

共 251 条

[41] Hormone replacement therapy and survival after colorectal cancer diagnosis [J].

Chan, Jennifer A. ;

Meyerhardt, Jeffrey A. ;

Chan, Andrew T. ;

Giovannucci, Edward L. ;

Colditz, Graham A. ;

Fuchs, Charles S. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (36) :5680-5686

[42] Estrogen replacement in surgical stage I and II endometrial cancer survivors [J].

Chapman, JA ;

DiSaia, PJ ;

Osann, K ;

Roth, PD ;

Gillotte, DL ;

Berman, ML .

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1996, 175 (05) :1195-1200

[43]

Cherry N, 2002, LANCET, V360, P2001

[44] Estrogen Plus Progestin and Breast Cancer Incidence and Mortality in Postmenopausal Women [J].

Chlebowski, Rowan T. ;

Anderson, Garnet L. ;

Gass, Margery ;

Lane, Dorothy S. ;

Aragaki, Aaron K. ;

Kuller, Lewis H. ;

Manson, JoAnn E. ;

Stefanick, Marcia L. ;

Ockene, Judith ;

Sarto, Gloria E. ;

Johnson, Karen C. ;

Wactawski-Wende, Jean ;

Ravdin, Peter M. ;

Schenken, Robert ;

Hendrix, Susan L. ;

Rajkovic, Aleksandar ;

Rohan, Thomas E. ;

Yasmeen, Shagufta ;

Prentice, Ross L. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 304 (15) :1684-1692

[45] Effects of hormone therapy on recurrence in endometrial cancer survivors: a nationwide study using the Korean Health Insurance Review and Assessment Service database [J].

Cho, Hyun-Woong ;

Ouh, Yung-Taek ;

Lee, Jae Kwan ;

Hong, Jin Hwa .

JOURNAL OF GYNECOLOGIC ONCOLOGY, 2019, 30 (04)

[46] PHASE-I PHARMACOKINETIC STUDY OF HIGH-DOSE PROGESTERONE AND DOXORUBICIN [J].

CHRISTEN, RD ;

MCCLAY, EF ;

PLAXE, SC ;

YEN, SSC ;

KIM, S ;

KIRMANI, S ;

WILGUS, LL ;

HEATH, DD ;

SHALINSKY, DR ;

FREDDO, JL ;

BRALY, PS ;

OQUIGLEY, J ;

HOWELL, SB .

JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (12) :2417-2426

[47] Menopausal Hormone Therapy and Lung Cancer-Specific Mortality Following Diagnosis: The California Teachers Study [J].

Clague, Jessica ;

Reynolds, Peggy ;

Henderson, Katherine D. ;

Sullivan-Halley, Jane ;

Ma, Huiyan ;

Lacey, James V., Jr. ;

Chang, Shine ;

Delclos, George L. ;

Du, Xianglin L. ;

Forman, Michele R. ;

Bernstein, Leslie .

PLOS ONE, 2014, 9 (07)

[48]

Clarke SC, 2002, BJOG-INT J OBSTET GY, V109, P1056, DOI 10.1111/j.1471-0528.2002.01544.x

[49] Liver fibrosis in women with chronic hepatitis C:: evidence for the negative role of the menopause and steatosis and the potential benefit of hormone replacement therapy [J].

Codes, Liana ;

Asselah, Tarik ;

Cazals-Hatem, Dominique ;

Tubach, Florence ;

Vidaud, Dominique ;

Parana, Raymundo ;

Bedossa, Pierre ;

Valla, Dominique ;

Marcellin, Patrick .

GUT, 2007, 56 (03) :390-395

[50] Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence [J].

Collaborative Group on Hormonal Factors in Breast Cancer .

LANCET, 2019, 394 (10204) :1159-1168

← 1 2 3 4 5 6 7 8 9 10 →